MBX News

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

(NASDAQ:MBX) Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291 Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291

September 4, 2025Clinical Trials

MBX Biosciences Q1 EPS $(0.71) Beats $(0.77) Estimate

MBX

May 12, 2025

JMP Securities Initiates Coverage On MBX Biosciences with Market Outperform Rating, Announces Price Target of $38

MBX

April 10, 2025

Guggenheim Reiterates Buy on MBX Biosciences, Maintains $44 Price Target

MBX

April 10, 2025

MBX Biosciences Q4 2024 GAAP EPS $(0.47) Beats $(0.59) Estimate, $262.1M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2024; Expected To Support Operations Into Mid-2027

MBX

March 17, 2025

MBX Biosciences Completes Enrollment In Phase 2 Avail Trial Of MBX 2109 For Hypoparathyroidism

MBX

March 3, 2025

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of Post-B

MBX

November 18, 2024